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Lung cancerAbstract Background: Tuberculosis is a chronic speciﬁc bacterial infection caused by bacteria of
the Mycobacterium tuberculosis. It remains one of the deadliest diseases in the world. It is the sec-
ond leading infectious cause of death after HIV infection. Adenosine deaminase (ADA) activity is
increased in various conditions such as liver disease, tuberculosis, typhoid, infective mononucleosis
and certain malignancies, especially those of haematopoietic origin.
Objective: The aim of the work was to assess the diagnostic value of ADA in pulmonary tuber-
culosis by comparing levels in sputum and serum.
Subjects and methods: The present study included 15 patients with active pulmonary tuberculo-
sis, 15 patients with pneumonia and 15 patients diagnosed as lung cancer. All patients were sub-
jected to: Full history taking, complete clinical examination, laboratory investigations, and plain
X-ray chest. Measurement of sputum and serum level of ADA of all patients using speciﬁc immu-
noassay method.
Results: There was a signiﬁcant increase in sputum ADA in tuberculous group in relation to the
other groups (mean sputum ADA was 159.76 ± 16.95, 84.34 ± 6.87 and 67.30 ± 7.47 U/L, respec-
tively). The mean serum ADA was 31.99 ± 8.85, 24.15 ± 4.22and 14.84 ± 2.43 U/L in tuberculous
group, pneumonia group and bronchogenic carcinoma group, respectively. There was a statistically
signiﬁcant increase in serum ADA in the tuberculous group in relation to the other groups (F 10.65,
P 0.001*). There was a statistically signiﬁcant positive correlation between sputum and serum ADA
(r= 0.75, P= 0.0001).
Conclusion: The results support the feasibility of using sputum ADA for diagnosis of pulmonary
tuberculosis.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.d.
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Tuberculosis (TB) is a chronic speciﬁc bacterial infection
caused by bacteria of the Mycobacterium tuberculosis [1].
TB remains one of the deadliest diseases in the world. It is
the second leading infectious cause of death after Human
Immunodeﬁciency Virus (HIV) infection [2]. It is an ancient
disease with the evidence of the organism being present in skel-
etons over 4000 years ago [3]. The earliest records that are con-
sistent with tuberculosis are the Egyptian wall paintings that
described the typical hunchback deformities and correlate with
the ﬁndings of spinal tuberculosis in mummies [4,5].
Adenosine deaminase (ADA) is an enzyme involved in
purine catabolism, the enzyme catalyzes the hydrolytic and
irreversible deamination of adenosine to inosine and deoxya-
denosine to deoxyinosine [5].
ADA has been extensively used in the diagnosis of tubercu-
lous pleural effusion, two isoenzymes, ADA1 and ADA2, have
been described [6].
In humans two different isozymes are encoded by different
genes, ADA1 is a single-chain Zn-binding protein and almost
all activities are attributed to this protein. ADA2 is believed to
be produced by monocytes and is found in negligible quanti-
ties. Mutations in the ADA1 gene, where expression is
blocked, cause immunodeﬁciency, whereas mutations that
cause overexpression cause hemolytic anemia [5].
Few studies have investigated the use of ADA activity in
material other than pleural ﬂuid. There are conﬂicting data
regarding the use of ADA activity in bronchoalveolar lavage
(BAL) as a diagnostic tool in pulmonary TB. Moreover,
patients may have relative contraindications that make bron-
choscopy difﬁcult to carry out, whereas sputum is easily
obtainable. However, sputum may be AFB-negative even in
the presence of the disease [6].
Subjects and methods
The study included 45 patients divided into three groups:
Group I: 15 patients diagnosed as active pulmonary tuber-
culosis. All patients had symptoms and signs of active pulmon-
ary tuberculosis, positive sputum smear for acid fast bacilli,
with X-ray ﬁndings consistent with active pulmonary
tuberculosis.
Group II: 15 patients diagnosed as pneumonia. All patients
had symptoms and signs of pneumonia, with X-ray ﬁndings
consistent with pneumonia and consolidation.
Group III: 15 patients diagnosed as bronchogenic
carcinoma. All patients had symptoms and signs of broncho-
genic carcinoma, with X-ray, CT and histopathological ﬁnd-
ings consistent with bronchogenic carcinoma.
After taking an informed consent, all subjects were sub-
jected to detailed history taking including symptoms, complete
clinical examination including general and local chest examin-
ations, anthropometric measurements, routine laboratory
investigations: including complete Blood count (CBC), liver
and renal function tests, erythrocyte sedimentation rate
(ESR) ﬁrst and second hours and chest X-ray (standard poste-
ro-anterior (PA) chest radiographs).
Sputum smears for acid-fast bacilli: Early morning expecto-
rated sputum specimens obtained after a deep, productive
cough were collected on three days from each patient in a cleantightly closed plastic disposable container properly labeled and
stained with Ziehl–Neelsen stain, quantitation scale for acid
fast bacillus smears was done [7].
Measurement of serum and sputum ADA in all patients [8]:
Early morning sputum samples and 5 cc venous blood samples
were obtained from all patients.
Blood samples were centrifuged at 3500 rpm for 10 min to
separate the sera. Sputum samples were homogenized with
70 milli-mol phosphate buffer (pH: 6.0) containing 0.5 mol
NaCl (1 ml sputum + 5 ml buffer). They were centrifuged at
5000 rpm for 30 min and ADA activity of the supernatant
was measured by Gusti method. Results were corrected by
multiplying with the dilution coefﬁcient.
We used Human Adenosine Deaminase ELISA kit with
Catalog Number: MBS733123.
All reagents stored at 2–8 C with valid period: six months
for samples like: Cell culture ﬂuid & body ﬂuid & tissue
homogenate Serum or blood plasma and for 96 tests.
Reagents handling: ADA reagent came in a liquid two
reagent system ready to use for both manual and automated
analyzer method. ADA controls and calibrator are in lyophi-
lized form, and need to be reconstituted with 1.0 of DI water
before use.
Assay procedure: ADA kit was used on automated clinical
chemistry analyzers.
Calibration: 0.9% saline and ADA calibrator were needed
for calibration. Results: The ADA results were printed out in
U/L.Results
The demographic data of the three studied groups as regards
age and sex were shown in Table 1.
In tuberculous patients sputum ADA ranged between 125.4
and 180.3 U/L with a mean value of 159.76 ± 16.95 U/L, in
pneumonia patients ranged between 72.5 and 95.3 U/L with
a mean value of 84.34 ± 6.87 U/L and in bronchogenic carci-
noma patients ranged between 51.8 and 83.2 U/L with a mean
value of 67.30 ± 7.47 U/L. There was statistically signiﬁcant
difference between the three studied groups regarding sputum
ADA (F= 25.65, P= 0.0001).
There was a signiﬁcant increase in sputum ADA in group I
than group II and group III and there was signiﬁcant increase
in sputum ADA in group II than group III (F= 25.65,
P1 = 0.0001, P2 = 0.0001, P3 = 0.0001 respectively) Table 2.
Serum ADA in group I ranged between 17.7 and 54.1 U/L
with a mean value of 31.99 ± 8.85 IU/L, in group II ranged
between 18.3 and 29.8 U/L with a mean value of
24.15 ± 4.22 U/L and in group III ranged between 11.3 and
19.2 U/L with a mean value of 14.84 ± 2.43 U/L. There was
a statistically signiﬁcant difference between the three studied
groups regarding serum ADA (F= 10.65, P= 0.001).
There was a signiﬁcant increase in serum ADA in group I
than group II (P< 0.01), also there was a signiﬁcant increase
in serum ADA in group I than group III (P< 0.001), Group
II serum ADA was signiﬁcantly increased than group III
(F= 10.65, P1 = 0.0022, P2 = 0.0001, P3 = 0.0001, respec-
tively) Table 2.
ADA sputum/serum ratio, in group I ranged between 3.30
and 9.25 with mean value of 5.31 ± 1.47, in group II ranged
between 2.99 and 4.84 with mean value of 3.59 ± 0.67 and













Range 125.4–180.3 I 72.5–95.3 51.8–83.2 25.65 0.0001*
Mean 159.76 84.34 67.30 0.0001* 0.0001*
S.D. 16.95 6.87 9.47 0.0001*
Serum ADA
Range 17.7–54.1 18.3–29.8 11.3–19.2 10.65 0.0022*
Mean 31.99 24.15 14.84 0.001* 0.0001*
S.D. 8.85 4.22 2.43 0.0001*
ADA sputum/serum ratio
Range 3.30–9.25 2.99–4.84 3.82–6.09 1.077 0.0685
Mean 5.31 3.59 4.59 0.208
S.D. 1.47 0.67 0.64 0.11
* P is signiﬁcant at 60.05, P1 comparison between group I and group II, P2 comparison between group I and group III, P3 comparison
between group II and group III, F=ANOVA test.
Table 1 Comparison between the three studied groups regarding demographic data.









Male 11 73.33% 9 60% 13 86.67% X2 = 2.65 0.1894
Female 4 26.67% 6 40% 2 13.33% 0.06
* P is signiﬁcant at 60.05, P1 comparison between group I and group II, P2 comparison between group I and group III,P3 comparison
between group II and group III, F=ANOVA test.
The diagnostic value of adenosine deaminase activity in pulmonary tuberculosis 105in group III ranged between 3.82 and 6.09 with mean value of
4.57 ± 0.64.
There was no statistically signiﬁcant difference between the
three studied groups regarding ratio ADA sputum/serum (P
0.0685, 0.208 and 0.11 respectively) Table 2.
The ROC curve was done to determine the cut off value for
both serum and sputum ADA to predict the presence or
absence of tuberculosis, the sputum ADA was more sensitive
and detective than serum ADA because the area under the
curve for sputum ADA is 1.00 and the cut off value of sputum
ADA was 93.4 U and the sensitivity of this marker was 100.0
and the speciﬁcity was 93.2% but in serum ADA the area
under the curve was 0.89 and the cut off value of serum
ADA was 17.9 U/L and the sensitivity of this marker was
93.3 and the speciﬁcity was 51.0% (Table 3, Fig. 1).Discussion
Mycobacterium tuberculosis infection is a main threat to man-
kind, with one third of the world population being infected. [9]
Over nine million new cases of tuberculosis and two million
deaths from this disease occur yearly worldwide. [10] The ris-
ing incidence of tuberculosis over the last decade has increased
the need to deﬁne the host factors that control the resistance to
tuberculosis. The chance of developing active disease after M.tuberculosis infection is about 10% in a lifetime in the non
HIV infected host.
The major risk factor for developing active tuberculosis is
immunodeﬁciency. Worldwide, malnutrition and starvation
are major causes of immunosuppression and increased suscep-
tibility to infectious diseases like tuberculosis [11,12].
Adenosine deaminase (ADA) is an enzyme involved in pur-
ine catabolism. The enzyme catalyzes the hydrolytic and irre-
versible deamination of adenosine to inosine and
deoxyadenosine to deoxyinosine. Two isoenzymes, ADA1
and ADA2 have been described [5,6].
ADA is an enzyme found in the majority of cells, but par-
ticularly in lymphocytes and monocytes. Its concentration is
inversely related to the degree of differentiation [8].
High ADA activity has been used as a valuable marker for
the diagnosis of tuberculous pleural effusion. As ADA is also
high with other diseases, such as bronchogenic cancer, sys-
temic lupus erythematousis, lymphoproliferative disorders,
empyema, mesothelioma and rheumatoid arthritis, the sensi-
tivity of the test is high and its speciﬁcity is low [13].
The present study was conducted on 45 patients, 15 patients
with active pulmonary tuberculosis (group I), 15 patients with
pneumonia (group II), and 15 patients diagnosed as lung can-
cer (group III).
In the current study there was a statistically signiﬁcant dif-
ference between the three studied groups regarding sputum
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was 159.76 ± 16.95 U/L, the mean value of sputum ADA in
pneumonia patients was 84.34 ± 6.87 U/L and the mean value
of sputum ADA in bronchogenic carcinoma patients was
67.30 ± 7.47 U/L. There was a statistically signiﬁcant differ-
ence between the three studied groups regarding sputum
ADA (F= 25.65, P= 0.0001).
There was a signiﬁcant increase in sputum ADA in group I
than group II and group III and there was a signiﬁcant increase
in sputum ADA in group II than group III (F= 25.65,
P1 = 0.0001, P2 = 0.0001, P3 = 0.0001, respectively).
In accordance with our ﬁndings Dimakou et al. [14] tried to
evaluate the diagnostic value of sputum ADA, ADA1 and
ADA2 activity in pulmonary tuberculosis and found that spu-
tum total ADA activity was signiﬁcantly higher in TB than in
lung cancer patients (median 18 U/L [range 3–70] vs. 6 U/L [2–
16]; P< 0.001) respectively and sputum ADA2 activity was
signiﬁcantly higher in TB compared to lung cancer patients
(9 U/L [0–65] vs. 5 U/L [0–12]; P= 0.001) respectively.
There was a statistically signiﬁcant difference between the
three studied groups regarding serum ADA. The mean value
of serum ADA in tuberculous patients was 31.99 ± 8.85 U/
L, the mean value of serum ADA in patients with pneumoniaTable 3 Positive predictive value of sputum and serum ADA in tu
Test result variable(s) Positive if greater than or equal toa
Sputum ADA 93.4000
Serum ADA 17.9000
a Positive predictive value (PPV) is the% probability that an individual h
Its value lies in that it combines the disease prevalence with test sensitivi
perfect laboratory test would have 100% sensitivity–speciﬁcity and predi
Figure 1 ROC curve assessing the ability of sputum and serum ADA
the ROC curve was 1.00 and 0.89 (95% CI, 0.00–1.00; and 0.791 and 0.
ADA.was 24.15 ± 4.22 U/L and the mean value of serum ADA in
patient with bronchogenic carcinoma was 14.84 ± 2.43 U/L
(F= 10.65, P= 0.001).
There was a signiﬁcant increase in serum ADA in group I
than group II and group III and group II show a signiﬁcant
increase than group III (P< 0.01) (F= 10.65, P1 = 0.0022,
P2 = 0.0001, P3 = 0.0001, respectively).
Afrasiabian et al. [15] found that the average (SD) of serum
ADA in TB and non-TB patients were 20.88 (±5.97) and
10.69 (±2.98) U/L, respectively (P value < 0.05). The best
cut-off point was 14 U/L. The calculated area under the recei-
ver operating characteristic (ROC) curve was 0.955 (95% CI,
0.914–0.995); sensitivity was 92.7% (95% CI, 84.7–100) and
speciﬁcity was 88.1% (95% CI, 78.3–97.8) (P < 0.001).
There was a statistically signiﬁcant positive correlation
between sputum and serum ADA (r= 0.75, P= 0.0001).
In the present study, there was no statistical signiﬁcant dif-
ference between the three studied groups regarding ratio ADA
sputum/serum (P 0.0685, 0.208 and 0.11, respectively).
Similarly Dilmac¸ et al. [16] tried to assess the diagnostic
value of adenosine deaminase activity in sputum of patients
with pulmonary tuberculosis, their aim was to determine and
compare sputum ADA activity in pulmonary tuberculosis,berculous patients.
Sensitivity Speciﬁcity PPV NPV
1.000 0.932 95.0 90.0
0.933 0.510 62.5 88.0
as the disease if he has a positive test. %PPV= TP/(TP + FP) · 100.
ty and speciﬁcity. The efﬁciency of the laboratory test lies in that A
ctive values of positivity and negativity.
to discriminate patients with tuberculous disease. The area under
989, P was 0.0001, 0.0001) respectively for both sputum and serum
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(COPD) patients in order to assess its diagnostic value.
Dilmac¸ et al. [16] found that sputum ADA activities in
tuberculous group were signiﬁcantly higher than the other
two groups (P< 0.01 for lung cancer group, P< 0.05 for
COPD) and this coincide with our ﬁndings. Also there was a
signiﬁcant increase in serum ADA activities in tuberculous
patients than bronchogenic carcinoma and chronic obstructive
pulmonary disease patients (P< 0.05) and this also coincide
with the present study.
In contrast to our result, Boonsarngsuk et al. [17] found
that BALF ADA had limited value in differentiating pulmon-
ary TB from some other pulmonary diseases. To differentiate
TB from solid tumor without endobronchial obstruction, a
combination of BALF ADA and TB PCR had marked addi-
tive diagnostic value.
In the current study the cut off value of sputum ADA was
93.4 IU/L, if the value was more than this cut off value the dis-
ease was present by 100.0%, while if the value was less than
93.4 U/L, the disease was absent by about 93.2%, i.e. the sen-
sitivity of this marker was 100.0%, speciﬁcity was 93.2%, posi-
tive predictive value was 95% and negative predictive value
was 90%.
On the other hand the cut off value of serum ADA was
17.9 U/L, if the value was more than this cut off value the dis-
ease was present by 93.3%, while if the value was less than
17.9 U/L, the disease was absent by about 51.0%, the sensitivity
of this marker was 93.3%, speciﬁcity was 51.0%, positive pre-
dictive value was 62% and negative predictive value was 88%.
Dimakou et al. [14] used a cut-off level of 16 U/L and 5 U/
L respectively for sputum total ADA and ADA2, sensitivity
and speciﬁcity were 55.6% and 100% for total ADA and
81.5% and 63.2% for ADA2.
Conclusion
Sputum ADA was signiﬁcantly increased in patients with pul-
monary tuberculosis than with pneumonia and lung cancer
patients.
The sputum ADA was more sensitive than serum ADA in
the diagnosis of pulmonary tuberculosis and there was a statis-
tically signiﬁcant positive correlation between sputum and
serum ADA.
Recommendation
Further studies are needed to measure ADA subtypes ADA1
and ADA2 separately to assess the diagnostic value of each
subtype in serum and sputum of tuberculous patients.
Further studies are needed to measure the level of sputum
and serum ADA before and after treatment of pulmonary
Tuberculosis to assess the effect of antituberculous drugs on
the level of ADA in sputum and serum.References
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